서재홍 교수의 진료시간표

서재홍 교수의 상세정보

• 1986 .03  ~  1992 .02  :  고려대학교 의과대학 의학과 학사
• 1996 .03  ~  1998 .02  :  고려대학교 대학원 종양내과학 석사
• 1998 .03  ~  2000 .08  :  고려대학교 대학원 종양내과학 박사

• 1992 .03  ~  1993 .02  :  고려대학교 의료원 수련의
• 1993 .03  ~  1997 .02  :  고려대학교 의료원 내과 전공의
• 1997 .03  ~  2001 .02  :  고려대학교 의료원 종양혈액내과 전임의
• 2001 .03  ~  2002 .08  :  고려대학교 의료원 종양혈액내과 임상조교수
• 2002 .09  ~  2005 .08  :  고려대학교 의과대학 종양내과 조교수
• 2005 .09  ~  2011 .08  :  고려대학교 의과대학 종양내과 부교수
• 2007 .03  ~  2009 .02  :  University of Massachusetts, Amherst, Animal Science Research Associate (Dr. Joseph D Jerry)
• 2011 .09  ~   :  고려대학교 의과대학 종양내과 교수

•  :  대한암학회 학술상 (사노피 신데라보) 2002 Biographical Record
•  :  Marquis Who’s Who in the World 2008, Silver Anniversary (25th Edition)
•  :  Marquis Who’s Who in the World 2009, 2010, 2011, 2012, 2013, 2014,2015, 2016, 2017, 2018, 2019
•  :  Marquis Who’s Who in Medicine and Healthcare 2009-2010
•  :  Marquis Who’s Who in 2017 Marquis Lifetime Award Winner 2017
•  :  2017 Albert Nelson Marquis Lifetime Achievement Award
•  :  The 2018 Albert Nelson Marquis Lifetime Achievement Award Winners
•  :  2019 Lifetime Achievement Award
•  :  International Biographical Center (IBC) Top 100 Health Professional 2012
•  :  American Biographical Institute Man of the Year 2011, 2012
•  :  Leading Health Professionals of the World 2013
•  :  Leading Achiever of the World 201
•  :  보건복지부 장관상 2017
•  :  고려의대 임상강의상, 2017
•  :  고려대학교 석탑연구상 2018

• 1997 .01  ~   :  항암화학요법연구회 정회원
• 2005 .01  ~   :  대한암예방학회 정회원
• 2006 .01  ~   :  한국임상암학회 이사
• 2007 .03  ~   :  대한내과학회 평생회원
• 2010 .01  ~   :  대한암학회 학술위원
• 2010 .01  ~   :  대한암협회 총무위원
• 2012 .03  ~   :  한국임상암학회 상임이사
• 2014 .03  ~   :  대한암학회 평생회원 및 이사
• 2015 .03  ~   :  한국유방암학회 회원 및 이사
• 2019  ~   :  대한종양내과학회 상임이사

• 2009 .03  ~   :  고려대학교 구로병원 유방암센터장
• 2010 .03  ~  2018 .01  :  고려대학교 구로병원 의과학연구소 소장
• 2012 .11  ~  2018 .10  :  보건복지부 임상현장발굴국가핵심중개연구 “유방암표적치료제 개발연구” 주관연구 책임자(6년간 총 80억)
• 2013 .04  ~   :  고려대학교 구로병원 연구중심병원 중점과제 책임연구자
• 2014 .01  ~  2018 .01  :  고려대학교 구로병원 종양혈액내과 과장
• 2017 .01  ~   :  고려대 자회사 주식회사 Theracan 대표이사
• 2017 .07  ~   :  암정복과제: HSP-90 inhibitor 신약개발 (총괄책임자: 총 25억)
• 2017 .09  ~   :  고려대학교 암연구소 소장
• 2018 .01  ~   :  고려대학교 구로병원 연구부원장
• 2018 .01  ~   :  고려대학교 구로병원 암센터장
• 2019 .07  ~   :  혁신형 의사과학자과제 (총괄책임자: 총 53억)
• 2020 .07  ~   :  연구중심병원 육성과제 총괄 및 유닛책임자 (총 358억)

• 2007 .03  ~  2009 .02  :  University of Massachusetts, Amherst, Animal Science Research Associate (Dr. Joseph D Jerry)

• [SCI] (C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition,)
• [SCI] (Investigation of B, C-ring truncated deguelin derivatives as heat shock protein 90(HSP90) inhibitor for use as anti-breast cancer agents)
• [SCI] (Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer.)
• [SCI] (Current strategies of endocrine therapy in elderly patients with breast cancer.)
• [SCI] (Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition)
• [SCI] (Inhibition of ubiquitin-specific protease 34 (USP34) induces epithelial-mesenchymal transition and promotes stemness in mammary epithelial cells.)
• [SCI] (Disulfiram Suppresses Cancer Stem-Like Properties and STAT3 Signaling in Triple-Negative Breast Cancer Cells)
• [SCI] (Overexpression of angiotensin II type 1 receptor in breast cancer cells induces epithelial-mesenchymal transition and promotes tumor growth and angiogenesis)
• [SCI] (Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer)
• [SCI] (Salinomycin possesses anti-tumor activity and inhibits breast cancer stem-like cells via an apoptosis-independent pathway)
• [SCI] (Salinomycin promote anoikis and decrease the CD44+/CD24-stem-like population via inhibition of STAT3 activation in MDA-MB-231 cells)
• [SCI] (YKL-40 expression could be as a poor prognostic marker in the breast cancer tissue)
• [SCI] (Association of aldehyde dehydrogenase 1 expression and biologically aggressive features in breast cancer)
• [SCI] (The relationship between preeclampsia, pregnancy-induced hypertension and maternal risk of breast cancer: a meta-analysis)
• [SCI] (A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer)
• [SCI] (The relationship between twin births and maternal risk of breast cancer: A meta-analysis)
• [SCI] (The relationship between Helicobacter pylori infection and the effects of chemotherapy in patients with advanced or metastatic gastric cancer)
• [SCI] (Bevacizumab for salvage treatment of metastatic breast cancer: A systemic review and meta-analysis of randomized controlled trials)
• [SCI] (A phase II study of vinorelbine monotherapy in anthracycline and taxane pretreated metastatic breast cancer)
• [SCI] (Association of a vascular endothelial growth factor (VEGF) gene 936 C/T polymorphism with breast cancer risk: a meta-analysis)
• [SCI] (Bevacizumab for salvage treatment of metastatic breast cancer: A systemic review and meta-analysis of randomized controlled trials)
• [SCI] (Association of a vascular endothelial growth factor (VEGF) gene 936 C/T polymorphism with breast cancer risk: a meta-analysis)
• [SCI] (A phase II study of vinorelbine monotherapy in anthracycline and taxane pretreated metastatic breast cancer)
• [SCI] (Association of a TGF-β1 509 C/T polymorphism with breast cancer risk: a meta-analysis)
• [SCI] (High serum YKL-40 is a poor prognostic marker in patients with advanced non-small cell lung cancer)
• [SCI] (Association of a progesterone receptor gene +331 G/A polymorphism with breast cancer risk: meta-analysis)
• [SCI] (Sustained co-cultivation with human placenta-derived MSCs enhance ALK5/Smad3 signaling in human breast epithelial cells, leading to EMT and differentiation)
• [SCI] (Docetaxel and epirubicin salvage regimen in anthracycline sensitive metastatic breast cancer patients relapsed after anthracycline-containing adjuvant therapy)
• [국외논문] (Meta-analysis of pre-operative aromatase inhibitor versustamoxifen in postmenopausal woman with hormone receptor-positive breast cancer)
• [국외논문] (Functional implication of Akt Activity and TGF-? signaling in Tamoxifen-resistanct Breast Cancer)
• [국외논문] (Extrinsic NO donor partially reverse Arginine Deiminase (ADI) induced anti-proliferative activity through NFB and Bcl-XL)
• [국외논문] (PPAR-γ ligand promote the growth of APC mutated colon cancer cell in vitro and in vivo)
• [국외논문] (Amniotic membrane might be applied to cancer treatment)
• [국외논문] (Epirubicin, Cisplatin, Oral UFT and Leucovorin Combination Chemotherapy in Advanced and Metastatic Esophageal Cancer)
• (Phase II study of a Gemcitabine and Cisplatin combination regimen in taxane resistant metastatic breast cancer)
• [국외논문] (uPAR expression under hypoxic conditions depends on iNOS modulated ERK phosphorylation in MDA-MB-231 breast carcinoma cell line)
• [국외논문] (Autocrine VEGF/VEGF Receptor-2 Growth Pathway Represents a Cyclooxygenase-2-Independent Target for Cycooxygenase-2 Inhibitor NS-398 in Colon Cancer Cells)

최종수정일 : 2023.05.09